Academic Endocrine Unit, Nuffield Department of Clinical Medicine, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Headington, Oxford OX3 7LJ, UK.
Hum Mol Genet. 2010 May 15;19(10):2028-38. doi: 10.1093/hmg/ddq084. Epub 2010 Feb 27.
GCMB is a member of the small transcription factor family GCM (glial cells missing), which are important regulators of development, present in vertebrates and some invertebrates. In man, GCMB encodes a 506 amino acid parathyroid gland-specific protein, mutations of which have been reported to cause both autosomal dominant and autosomal recessive hypoparathyroidism. We ascertained 18 affected individuals from 12 families with autosomal recessive hypoparathyroidism and have investigated them for GCMB abnormalities. Four different homozygous germline mutations were identified in eight families that originate from the Indian Subcontinent. These consisted of a novel nonsense mutation R39X; a missense mutation, R47L in two families; a novel missense mutation, R110W; and a novel frameshifting deletion, I298fsX307 in four families. Haplotype analysis, using polymorphic microsatellites from chromosome 6p23-24, revealed that R47L and I298fsX307 mutations arose either as ancient founders, or recurrent de novo mutations. Functional studies including: subcellular localization studies, EMSAs and luciferase-reporter assays, were undertaken and these demonstrated that: the R39X mutant failed to localize to the nucleus; the R47L and R110W mutants both lost DNA-binding ability; and the I298fsX307 mutant had reduced transactivational ability. In order to gain further insights, we undertook 3D-modeling of the GCMB DNA-binding domain, which revealed that the R110 residue is likely important for the structural integrity of helix 2, which forms part of the GCMB/DNA binding interface. Thus, our results, which expand the spectrum of hypoparathyroidism-associated GCMB mutations, help elucidate the molecular mechanisms underlying DNA-binding and transactivation that are required for this parathyroid-specific transcription factor.
GCMB 是小转录因子家族 GCM(glial cells missing)的成员,该家族在脊椎动物和一些无脊椎动物中都有存在,是发育的重要调节剂。在人类中,GCMB 编码一个 506 个氨基酸的甲状旁腺特异性蛋白,其突变已被报道可导致常染色体显性和常染色体隐性甲状旁腺功能减退症。我们从 12 个常染色体隐性甲状旁腺功能减退症的家庭中确定了 18 名受影响的个体,并对他们进行了 GCMB 异常的调查。在来自印度次大陆的 8 个家庭中发现了 4 种不同的纯合生殖系突变。这些突变包括一个新的无义突变 R39X;在两个家庭中存在 R47L 错义突变;一个新的错义突变 R110W;以及在四个家庭中存在的一个新的移码缺失 I298fsX307。使用来自 6p23-24 染色体的多态性微卫星进行单体型分析表明,R47L 和 I298fsX307 突变要么是古老的创始人,要么是新的重复突变。进行了包括亚细胞定位研究、EMSA 和荧光素酶报告基因分析在内的功能研究,这些研究表明:R39X 突变体未能定位到细胞核;R47L 和 R110W 突变体均失去 DNA 结合能力;而 I298fsX307 突变体的转录激活能力降低。为了进一步深入了解,我们对 GCMB DNA 结合域进行了 3D 建模,结果表明 R110 残基可能对形成 GCMB/DNA 结合界面一部分的螺旋 2 的结构完整性很重要。因此,我们的研究结果扩展了与甲状旁腺功能减退症相关的 GCMB 突变谱,有助于阐明 DNA 结合和转录激活的分子机制,这些机制是这种甲状旁腺特异性转录因子所必需的。